Raymond James: Madrigal Pharmaceuticals (MDGL) Coverage Initiated.

June 29, 2018 - By Loretta Love

What’s Raymond James’s Current Rate of Madrigal Pharmaceuticals (MDGL)

Madrigal Pharmaceuticals (MDGL) have new “Market Perform” rating issued by Raymond James’s Analysts. On Thursday, 28 June the broker has started coverage of MDGL shares.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Ratings Coverage

In total 8 analysts cover Madrigal Pharmaceuticals (MDGL). “Buy” rating has 6, “Sell” are 0, while 2 are “Hold”. (MDGL) has 75% bullish analysts. 12 are the (MDGL)’s ratings reports on Jun 29, 2018 according to StockzIntelligence Inc. On Friday, March 23 the company was initiated by Goldman Sachs. In Tuesday, June 19 report Evercore downgraded the stock to “In-Line” rating. On Thursday, February 8 the rating was maintained by Evercore with “Outperform”. On Tuesday, January 30 the firm has “Buy” rating given by H.C. Wainwright. On Monday, April 16 the firm has “Hold” rating by Oppenheimer given. On Thursday, May 31 Goldman Sachs maintained Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) with “Buy” rating. On Friday, March 16 the firm earned “Buy” rating by Roth Capital. On Thursday, May 31 the stock has “Buy” rating by Oppenheimer. On Thursday, May 31 the stock of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) earned “Buy” rating by JMP Securities. On Friday, June 1 the company was maintained by H.C. Wainwright.

Ticker’s shares touched $281.62 during the last trading session after 1.32% change.Currently Madrigal Pharmaceuticals, Inc. is uptrending after 630.32% change in last June 29, 2017. MDGL has 39,703 shares volume. MDGL outperformed the S&P 500 by 617.75%.

On August, 9 is anticipated Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)’s earnings report, as reported by RTT. This year’s earnings per share analyst estimate is anticipated to be $-0.60. That is 13.04 % up compareed to $-0.69 earnings per share for last year. 33.33 % negative EPS growth is what Wall Street’s sees after $-0.45 reported EPS previous quarter.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases.The company has $4.29 billion market cap. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor ß-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia.Currently it has negative earnings. It is also developing MGL-3745, a THR-ß-selective small molecule that is in preclinical trials.

For more Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) news published briefly go to: Fool.com, Streetinsider.com, Nasdaq.com, Fool.com or Benzinga.com. The titles are as follows: “Cash for NASH: 2 Top Biotech Takeover Targets and 3 Potential Buyers” published on June 15, 2018, “Pre-Open Movers 05/31: (MDGL) (VTVT) (GM) Higher; (CLSD) (CRSP) (DLTR) Lower (more…)” on May 31, 2018, “Why Viking Therapeutics Stock Is On Fire Today” with a publish date: May 31, 2018, “Here’s Why Madrigal Pharmaceuticals Is Skyrocketing Today” and the last “Maxim Explains Viking Therapeutics’ Sympathy Move With Madrigal” with publication date: June 02, 2018.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: